23 / 54
First-line CT
±
Pembrolizumab for metastatic non-squamous NSCLC
KEYNOTE-189 trial
Gandhi L, et al. N Engl J Med 378:2078-2092, 2018
Primary endpoints: OS & PFS
Secondary endpoints: RR, duration of response & safety
41.3% Crossover
±
88% smokers
17% stable Brain Mets
±
30% PD-L1 ≥ 50%
±
70% Carboplatin